

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 22, 2025

Phosflow Perm Buffer III 125mL

RRID:AB_2869118

Type: Antibody

Proper Citation

(BD Biosciences Cat# 558050, RRID:AB_2869118)

Antibody Information

URL: http://antibodyregistry.org/AB_2869118

Proper Citation: (BD Biosciences Cat# 558050, RRID:AB_2869118)

Clonality: unknown

Comments: Applications: Intracellular staining (flow cytometry)

Antibody Name: Phosflow Perm Buffer III 125mL

Description: This unknown targets

Antibody ID: AB_2869118

Vendor: BD Biosciences

Catalog Number: 558050

Record Creation Time: 20231110T031935+0000

Record Last Update: 20240725T031114+0000

Ratings and Alerts

No rating or validation information has been found for Phosflow Perm Buffer III 125mL.

No alerts have been found for Phosflow Perm Buffer III 125mL.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Mandarano AH, et al. (2023) DRAK2 contributes to type 1 diabetes by negatively regulating IL-2 sensitivity to alter regulatory T cell development. *Cell reports*, 42(2), 112106.

Höfle J, et al. (2022) Engagement of TRAIL triggers degranulation and IFN γ production in human natural killer cells. *EMBO reports*, 23(8), e54133.

Kofla G, et al. (2022) Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade. *Oncoimmunology*, 11(1), 2068109.

Liu H, et al. (2022) Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates Fc γ R-independent GITR agonism and antitumor activity. *Cell reports. Medicine*, 3(6), 100660.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. *Cell*, 185(8), 1414.

De Simone G, et al. (2021) Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. *Immunity*, 54(9), 2089.

Smith BD, et al. (2021) Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. *Molecular cancer therapeutics*, 20(11), 2098.

Alexander AF, et al. (2021) Single-cell secretion analysis reveals a dual role for IL-10 in restraining and resolving the TLR4-induced inflammatory response. *Cell reports*, 36(12), 109728.